Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Aims : To analyse the expression of α v β 6, an epithelial integrin involved in wound healing and tumorigenesis, in various human carcinoma types. Methods and results : A new monoclonal antibody to the human β 6 subunit, 5C4, was used to locate α v β 6 in 157 cancers of gastroenteropancreatic and 21 of lung origin. The data were validated by analysis of α v β 6 extracted from histological sections. α v β 6 integrin showed strongest expression in 34 pancreatic ductal adenocarcinomas (mean score 2.88 ± 0.52), followed by 24 intestinal‐type gastric carcinomas (1.45 ± 1.06) and eight lung adenocarcinomas (1.37 ± 1.1). Moderate expression was found in 31 diffuse‐type gastric carcinomas (0.94 ± 0.83), seven duodenal adenocarcinomas (0.8 ± 1.34) and 26 colorectal adenocarcinomas (0.76 ± 0.71). Little α v β 6 was seen in seven liver cell carcinomas and six neuroendocrine tumours. Well‐differentiated carcinomas expressed more β 6 than poorly differentiated tumours. Peritumoral epithelial tissues where α v β 6‐expressing tumours arose also expressed α v β 6. There was no correlation between expression of α v β 6 and its ligands tenascin and fibronectin in pancreatic and gastric carcinomas. Spheroid formation by pancreatic carcinoma cell lines led to α v β 6 up‐regulation, but appeared independent of classical ligand binding to α v β 6. Conclusions : Our findings indicate that: (i) α v β 6 is overexpressed in pancreatic adenocarcinomas; (ii) α v β 6‐positive carcinomas originate from α v β 6‐expressing tissues; (iii) α v β 6 expression in tumours seems to be regulated independently from that of its ligands tenascin and fibronectin; and (iv) in‐vitro overexpression of α v β 6 in pancreatic carcinoma cell lines accompanies spheroid formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Cited by
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
TGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
The roles of integrin αvβ6 in cancer
Niu, J., & Li, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.012 · Cited by 178
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143
Metadata
- Authors
- Sipos, B., Hahn, D., Carceller, A., Piulats, J., Hedderich, J., Kalthoff, H., Goodman, S. L., Kosmahl, M., & Klöppel, G.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2004-08-26
- Volume
- 45
- Issue
- 3
- Pages
- 226-236
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2029851814
- Cited by
- 124
- References
- 1
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. https://app.cochat.ai/papers/10.1111/j.1365-2559.2004.01919.x
- The paper
- Sipos, B., Hahn, D., Carceller, A., Piulats, J., Hedderich, J., Kalthoff, H., Goodman, S. L., Kosmahl, M., & Klöppel, G. (2004). Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. https://doi.org/10.1111/j.1365-2559.2004.01919.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.